This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Sprycel
  • /
  • Study of Dasatinib in Children and Adolescents Wit...
Clinical trial

Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia

Read time: 2 mins
Last updated:22nd Feb 2006
Identifier: NCT00306202

The purpose of this clinical research study was to establish a recommended phase 2 once daily (QD) dose of dasatinib and to assess the efficacy of the investigational drug for relapsed or refractory (resistant to previous treatment) leukemia in children and adolescents. The side effects that this oral investigational drug may have in children, and the levels of the drug in the blood, will be studied at different doses.

Study Type: Interventional
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of SRC/ABL Tyrosine Kinase Inhibitor Dasatinib [BMS-354825] in Children and Adolescents With Relapsed or Refractory Leukemia, Protocol ITCC 005
Enrollment: 63
Actual Study Start Date: February 22, 2006
Estimated Study Completion Date: October 4, 2022
Primary Completion Date: May 25, 2011 (Final data collection date for primary outcome measure)

- Experimental:
Stratum 1 (Ph+ CP-CML)
- Experimental: Stratum 2/3 (Ph+ ALL or AP/BP-CML)
- Experimental: Stratum 4 (Ph- ALL/AML)

Category Value
Date last updated at source 2017-09-26
Expected enrolment 63
Study start date 2006-02-22
Estimated primary completion date 2011-05-25

View full details